Search Results

Recro Pharma, Inc. announced that company management will host a webcast to discuss the company’s recently announced acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro.

IRISYS, LLC announced today that it has been issued U.S. Patent No. 11,033,530, Liposomal Anticancer Compositions.

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro.

IRISYS LLC, a pharmaceutical contract development and manufacturing company (CDMO), provides contract development and GMP manufacturing services to BioCorRx Pharmaceuticals, Inc., for a sterile naltrexone sub-cutaneous implant, also known as BICX102, which is meant to help in the treatment of opioid use disorder (OUD) and the prevention of

IRISYS LLC, a pharmaceutical contract manufacturing and development organization (CDMO), announced its third contract for production and manufacturing in partnership with TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company located in Austin, TX

Contract from National Institutes of Health (NIH) is Largest of Four Prime Contracts Awarded IRISYS Since 2010

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has signed a contract with IRISYS LLC for the production of AS1411, Qualigen’s lead drug candidate for the treatment of viral diseases including COVID-19. Preclinical studies at the University of Louisville’s (UofL) prestigious Center for Infectious Disease

Recro Pharma, Inc. today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result of its acquisition and successful integration of IriSys, Inc. into the organization.